Tag: Emtora Biosciences

Cancer Insight Helps Biotech Startups Win over $31M in CPRIT Funding
Articles, Featured

Cancer Insight Helps Biotech Startups Win over $31M in CPRIT Funding

Developing new drug therapies for cancer treatment can be difficult, expensive, and take years before successfully reaching the U.S. market. Where do biotech companies find funding to support research and development? Many researchers apply for federal grants out of the $2.5 billion annually set aside for the U.S. Small Business Innovation Research Program, also known as SBIR, and the Small Business Technology Transfer program, or STTR. These two initiatives are the largest source of federally funded early-stage, high-risk funding for startup companies. Read more: What You Should Know about Non-Diluting Federal SBIR, STTR Funding The state of Texas also contributes early-stage funding from the Cancer Prevention and Research Institute of Texas (CPRIT) for bioscience economic devel...
Rapamycin Holdings Becomes Emtora Biosciences, Gains New CEO
Articles, Featured

Rapamycin Holdings Becomes Emtora Biosciences, Gains New CEO

San Antonio-based Rapamycin Holdings, Inc. announced its rebranding Tuesday as Emtora Biosciences with Dr. Carole Spangler Vaughn as its new chief executive officer. Dan Hargrove recruited Spangler Vaughn as his replacement after hiring her as a consultant for the privately-held drug development company about six months ago. The drug company is commercializing a ground-breaking cancer prevention drug, eRapa™, a proprietary reformulation of the generic drug Rapamycin. The changes reflect the company's goal to get the drug through the regulatory approval process faster for a quicker market launch. “I’ve brought drugs to the market before,” Spangler Vaughn told Startups San Antonio. “With my background and experience, I can ask detailed questions about the science, then ask about the dr...